Global Bronchodilators Market Size

Bronchodilators Market Analysis

The bronchodilators market studied is expected to grow with an estimated CAGR of 4.7%, over the forecast period.

Substantial increase in the number of patients with respiratory disorders on an account of COVID-19 are projected to trigger the demand for bronchodilators across the globe. Several research studies suggest that the use of bronchodilator medications in treating COVID-19 patients can facilitate normal breathing and functional improvements. These medications are mainly useful in confirmed or suspected COVID-19 cases with reactive airway diseases. A June 2021 study published in Respiratory Medicine Journal, aimed at confirming the level of bronchodilator reversibility in SARSCoV2 patients undertaking multidisciplinary pulmonary rehabilitation after the acute phase. The study concluded that the use of bronchodilators should be considered in post-COVID-19 patients as it can encourage functional improvements in the lungs for normal breathing. However, some research studies contrast the usefulness of bronchodilators and conclude that no significant changes are observed in affected patients with minimal improvement in clinical outcomes for reducing the risk of mortality. For instance, recently, in 2021, a retrospective cohort study was carried to evaluate the association between the length of COVID-19 pneumonia patient stay in the hospitals and the use of inhaled bronchodilators in Spain. The results concluded from the study did not specify any notable health improvements among patients. As a result, the bronchodilators market is anticipated to be moderately impacted by the pandemic.

The studied market growth can be attributed to a variety of factors, such as the rising prevalence of respiratory diseases globally coupled with increased levels of air pollution, the surge in the number of smokers, and propelling incidence of infectious diseases among the elderly population significantly contributing toward the risk of developing lung disorders, and are collectively driving the market growth.

One of the key parameters responsible for the growth of the bronchodilators market is the gradual decrease in functionality of lungs along with the age of an individual. Thus, these cognitive and physical changes usually make normal breathing difficult in the elderly, thereby, driving the growth of the market. The geriatric population is more vulnerable to respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC), in 2019, around 4,069,278 Americans aged above 65 years were living with asthma. Since bronchodilators play a vital role in maintaining optimal airflow within the lungs of these patients, this is likely to boost the demand for bronchodilators in near future. Additionally, a rising number of product launches and approvals are expected to have a positive impact on the demand for bronchodilators within the patient population. For instance, in July 2020, EVA Pharma launched 'Inhalex', the first Egyptian medication for COPD with a 24-hour lasting effect. This product launch is projected to reduce the cost of the treatment of COPD patients to half. On the contrary, possible side effects such as tremors, coughs, increased heart rate, and nervousness are likely to obstruct the market growth over the forecast period.